| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3944978 | Gynecologic Oncology | 2007 | 5 Pages |
Abstract
Overall, oral lenalidomide was well tolerated and may have some activity as a single agent in this heavily pre-treated population. Further studies combining lenalidomide with cytotoxic treatments may be warranted in this disease setting.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Mallory M. Zhang, John K. Chan, Amreen Husain, Hong-Yan Guo, Nelson N.H. Teng,